Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Kirsten Timms"'
Autor:
Jeffrey A. How, Amir A. Jazaeri, Bryan Fellman, Molly S. Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S. Lanchbury, Kirsten Timms, Karen H. Lu, Melinda S. Yates
Publikováno v:
Cancers, Vol 13, Iss 5, p 946 (2021)
New therapies, such as poly-ADP ribose polymerase inhibitors (PARPi), and immunotherapy treatments have generated great interest in enhancing individualized molecular profiling of epithelial ovarian cancer (EOC) to improve management of the disease.
Externí odkaz:
https://doaj.org/article/8c9618906aa540899668aa9715dbd307
Autor:
Robert D Morgan, Andrew R Clamp, Bethany M Barnes, Kirsten Timms, Helene Schlecht, Laura Yarram-Smith, Yvonne Wallis, Mikel Valganon-Petrizan, Suzanne MacMahon, Rhian White, Sian Morgan, Sarah McKenna, Emma Hudson, Laura Tookman, Angela George, Ranjit Manchanda, Sudha S Sundar, Shibani Nicum, James D Brenton, Rebecca S Kristeleit, Susana Banerjee, Iain A McNeish, Jonathan A Ledermann, Stephen S Taylor, D Gareth R Evans, Gordon C Jayson
Publikováno v:
Morgan, R D, Clamp, A R, Barnes, B M, Timms, K, Schlecht, H, Yarram-Smith, L, Wallis, Y, Valganon-Petrizan, M, Macmahon, S, White, R, Morgan, S, Mckenna, S, Hudson, E, Tookman, L, George, A, Manchanda, R, Sundar, S S, Nicum, S, Brenton, J D, Kristeleit, R S, Banerjee, S, Mcneish, I A, Ledermann, J A, Taylor, S S, Evans, D G & Jayson, G C 2023, ' Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study ', International Journal of Gynecological Cancer . https://doi.org/10.1136/ijgc-2022-004211
ObjectiveOlaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the first year of routine homologo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb793cc9d756983a33fbb917e7372e8
https://doi.org/10.1136/ijgc-2022-004211
https://doi.org/10.1136/ijgc-2022-004211
Autor:
Harsimar B. Kaur, Kirsten Timms, Sanjana Murali, Edward M. Schaeffer, Daniela C. Salles, Olivier Cussenot, Robert S. Brown, Geraldine Cancel-Tassin, William B. Isaacs, Emmanuel S. Antonarakis, Tamara L. Lotan, Jerry S. Lanchbury, Andrea L. Richardson
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis
Autor:
Anil K. Sood, Robert L. Coleman, Selanere Mangala, Placede Tshiaba, Keith A. Baggerly, Wei Hu, Thomas P. Conrads, Kirsten Timms, Chris Neff, Ying Wang, Kari L. Ring, Shannon N. Westin, Karen H. Lu, K.M. Darcy, R.L. Dood, G.L. Maxwell, Russell Broaddus, Gabriel Lopez-Berestein, Shannon Gallagher, Jean H. Siedel
Publikováno v:
Gynecol Oncol
BACKGROUND: Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of alterations in the HR pathway in en
Autor:
Hillary Zalaznick, Benjamin Clegg, Elizabeth Cogan, Michael Perry, Jeffrey Trost, Debora Mancini-DiNardo, Alexander Gutin, Jerry Lanchbury, Kirsten Timms
Publikováno v:
Gynecologic Oncology. 166:S86-S87
Autor:
Kirsten Timms, Emmanuel S. Antonarakis, Jessica Hicks, Colin C. Pritchard, Bruce J. Trock, Angelo M. De Marzo, Tamara L. Lotan, Daniela C. Salles, Harsimar B. Kaur, William B. Isaacs, Minh Nguyen, Jerry S. Lanchbury, Sanjana Murali
Publikováno v:
Clinical Cancer Research. 26:4869-4881
Purpose:The ATM (ataxia telangiectasia mutated) gene is mutated in a subset of prostate cancers, and ATM mutation may confer specific therapeutic vulnerabilities, although ATM-deficient prostate cancers have not been well-characterized.Experimental D
Autor:
Noreen Gleeson, John J. O'Leary, Dearbhaile M. O'Donnell, Aoife Carr, Britta K. Stordal, Liam Grogan, Stephen F. Madden, Angela M. Farrelly, Kirsten Timms, Mark Bates, Sinead Toomey, Roshni Kalachand, Bryan T. Hennessy, Ciaran O'Riain, Sharon O'Toole, Oscar S. Breathnach
Publikováno v:
Obstetrics & Gynecology Science
Obstetrics & Gynecology Science, Vol 63, Iss 5, Pp 643-654 (2020)
Obstetrics & Gynecology Science, Vol 63, Iss 5, Pp 643-654 (2020)
Objective\ud The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2
Autor:
Joshua J. Gruber, Kirsten Timms, Nadine Tung, Vered Stearns, Daniel P. Silver, Andrea L. Richardson, Ryan Bernhisel, Judy Garber, Shaveta Vinayak, James M. Ford, Melinda L. Telli, Virginia G. Kaklamani, Chris Neff, Steven J. Isakoff, Sunil Badve, William J. Gradishar, Sylvia Adams, Roisin M. Connolly, Charles Chu
Publikováno v:
Clinical Cancer Research. 26:2704-2710
Purpose: Patients with triple-negative breast cancer (TNBC) with homologous recombination deficient tumors achieve significantly higher pathologic complete response (pCR) rates when treated with neoadjuvant platinum-based therapy. Tumor-infiltrating
Autor:
Yesim Gökmen-Polar, Lajos Pusztai, Richard D. Kennedy, Alastair M. Thompson, Priyanka Sharma, Kirsten Timms, Daniel F. Hayes, Gabriel N. Hortobagyi, Peggy L. Porter, Debu Tripathy, Hannah M. Linden, Shane R. Stecklein, Andrew K. Godwin, William E. Barlow, Sunil Badve
Publikováno v:
Cancer Research. 81:GS3-05
Introduction/Aims: DDIR signature, HRD, and stromal tumor infiltrating lymphocytes (sTIL) have each been associated with favorable outcomes in early stage TNBC. We assessed the overlap between these markers and created prognostic categories based on
Autor:
Zhongwu Lai, Darren Hodgson, Brian Dougherty, J. Carl Barrett, Tsveta Milenkova, Elizabeth A. Harrington, Jessica S Brown, Eric Pujade-Lauraine, Simon Dearden, Alexandra Leary, Jerry S. Lanchbury, Michael C. Perry, Cathy E. Elks, Kirsten Timms
Publikováno v:
Gynecologic oncology. 163(3)
Objective Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain regarding tumor